{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T08:30:12Z","timestamp":1792657812288,"version":"4.5.0"},"reference-count":30,"publisher":"American Academy of Pediatrics (AAP)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,10,1]]},"abstract":"<jats:sec>\n                  <jats:title>OBJECTIVES:<\/jats:title>\n                  <jats:p>To report clinical course, etiology, management, and long-term outcomes of children suffering from Stevens-Johnson syndrome (SJS) or toxic epidermal necrolysis (TEN).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>METHODS:<\/jats:title>\n                  <jats:p>We conducted a study of all pediatric patients with SJS or TEN admitted between 2000 and 2007 to the Hospital for Sick Children and Children's Hospital Boston, and particular attention was paid to clinical manifestations, etiology, mortality, and long-term outcomes.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESULTS:<\/jats:title>\n                  <jats:p>We identified 55 cases of SJS (n = 47), TEN (n = 5), or SJS\/TEN overlap syndrome (n = 3). Drugs were identified as the most likely etiologic agent in 29 children (53%); antiepileptic drugs were the most common agents (n = 16), followed by sulfonamide antibiotics (n = 7) and chemotherapy drugs (n = 2). Acute Mycoplasma pneumoniae infection was confirmed in 12 children (22%), and herpes simplex virus was confirmed in 5 children (9%). Treatment regimens differed significantly between participating sites and included systemic antimicrobial agents (67%), systemic corticosteroids (40%), and antiviral drugs (31%). Intravenous immunoglobulin was administered to 21 children (38%), of whom 8 received concomitant systemic corticosteroids. Ten children (18%) had recurrence of SJS up to 7 years after the index episode, and 3 experienced multiple recurrences. Twenty-six children (47%) suffered long-term sequelae that mostly involved the skin and eyes.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>CONCLUSIONS:<\/jats:title>\n                  <jats:p>Mortality rate in children was lower than that reported in adults, but half of affected children suffered long-term complications. The recurrence rate of SJS was high (1 in 5), which suggests vulnerability and potential genetic predisposition. In the absence of standardized management guidelines for these conditions, treatment regimens differed significantly between participating institutions.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1542\/peds.2010-3322","type":"journal-article","created":{"date-parts":[[2011,9,3]],"date-time":"2011-09-03T04:51:34Z","timestamp":1315025494000},"page":"723-728","source":"Crossref","is-referenced-by-count":139,"title":["Recurrence and Outcomes of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Children"],"prefix":"10.1542","volume":"128","author":[{"given":"Yaron","family":"Finkelstein","sequence":"first","affiliation":[{"name":"Department of Pediatrics and"},{"name":"Divisions of Emergency Medicine and"},{"name":"Clinical Pharmacology and Toxicology, and"},{"name":"Departments of Pediatrics,"},{"name":"Pharmacology and Toxicology, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gordon S.","family":"Soon","sequence":"additional","affiliation":[{"name":"Department of Pediatrics and"},{"name":"Departments of Pediatrics,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Acuna","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology Research Program, Division of Emergency Medicine, Children's Hospital Boston, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathew","family":"George","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology Research Program, Division of Emergency Medicine, Children's Hospital Boston, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Pope","sequence":"additional","affiliation":[{"name":"Department of Pediatrics and"},{"name":"Departments of Pediatrics,"},{"name":"Section of Dermatology, Hospital for Sick Children, Toronto, Ontario, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinya","family":"Ito","sequence":"additional","affiliation":[{"name":"Department of Pediatrics and"},{"name":"Clinical Pharmacology and Toxicology, and"},{"name":"Departments of Pediatrics,"},{"name":"Pharmacology and Toxicology, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil H.","family":"Shear","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology and Toxicology, and"},{"name":"Pharmacology and Toxicology, and"},{"name":"Dermatology, University of Toronto, Toronto, Ontario, Canada; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gideon","family":"Koren","sequence":"additional","affiliation":[{"name":"Department of Pediatrics and"},{"name":"Clinical Pharmacology and Toxicology, and"},{"name":"Departments of Pediatrics,"},{"name":"Pharmacology and Toxicology, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael W.","family":"Shannon","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology Research Program, Division of Emergency Medicine, Children's Hospital Boston, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Facundo","family":"Garcia-Bournissen","sequence":"additional","affiliation":[{"name":"Department of Pediatrics and"},{"name":"Clinical Pharmacology and Toxicology, and"},{"name":"Departments of Pediatrics,"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"417","published-online":{"date-parts":[[2011,10,1]]},"reference":[{"issue":"2","key":"2021120823450165600_B1","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.tox.2004.12.022","article-title":"Clinical heterogeneity of drug hypersensitivity","volume":"209","author":"Roujeau","year":"2005","journal-title":"Toxicology"},{"issue":"1","key":"2021120823450165600_B2","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1007\/s00134-009-1659-1","article-title":"Severe cutaneous adverse reactions: emergency approach to non-burn epidermolytic syndromes","volume":"36","author":"Struck","year":"2009","journal-title":"Intensive Care Med"},{"issue":"2","key":"2021120823450165600_B3","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1046\/j.1523-1747.2000.00061.x","article-title":"SCORTEN: a severity-of-illness score for toxic epidermal necrolysis","volume":"115","author":"Bastuji-Garin","year":"2000","journal-title":"J Invest Dermatol"},{"issue":"2","key":"2021120823450165600_B4","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2008-1923","article-title":"Medications as risk factors of Stevens-Johnson syndrome and toxic epidermal necrolysis in children: a pooled analysis","volume":"123","author":"Levi","year":"2009","journal-title":"Pediatrics"},{"issue":"2","key":"2021120823450165600_B5","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.jaad.2006.04.048","article-title":"Toxic epidermal necrolysis","volume":"56","author":"Pereira","year":"2007","journal-title":"J Am Acad Dermatol"},{"issue":"24","key":"2021120823450165600_B6","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1056\/NEJM199512143332404","article-title":"Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis","volume":"333","author":"Roujeau","year":"1995","journal-title":"N Engl J Med"},{"issue":"2","key":"2021120823450165600_B7","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1051\/medsci\/2006222188","article-title":"Epidermal necrolysis: mechanisms of keratinocyte apoptosis [in French]","volume":"22","author":"Roujeau","year":"2006","journal-title":"Med Sci (Paris)"},{"issue":"1","key":"2021120823450165600_B8","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1001\/archderm.1990.01670250049006","article-title":"The incidence of erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis: a population-based study with particular reference to reactions caused by drugs among outpatients","volume":"126","author":"Chan","year":"1990","journal-title":"Arch Dermatol"},{"issue":"2","key":"2021120823450165600_B9","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.burns.2009.06.213","article-title":"Toxic epidermal necrolysis (Lyell's disease)","volume":"36","author":"Lissia","year":"2010","journal-title":"Burns"},{"issue":"7","key":"2021120823450165600_B10","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1212\/01.WNL.0000156354.20227.F0","article-title":"Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis in new users of antiepileptics","volume":"64","author":"Mockenhaupt","year":"2005","journal-title":"Neurology"},{"issue":"1","key":"2021120823450165600_B11","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/sj.jid.5701033","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs: the EuroSCAR-study","volume":"128","author":"Mockenhaupt","year":"2008","journal-title":"J Invest Dermatol"},{"issue":"7","key":"2021120823450165600_B12","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/0895-4356(96)00035-2","article-title":"Epidemiology of erythema exsudativum multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis in Germany (1990\u20131992): structure and results of a population-based registry","volume":"49","author":"Rzany","year":"1996","journal-title":"J Clin Epidemiol"},{"issue":"13","key":"2021120823450165600_B13","doi-asserted-by":"crossref","first-page":"965","DOI":"10.2165\/00002018-200225130-00006","article-title":"Erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis in children: a review of 10 years' experience","volume":"25","author":"Forman","year":"2002","journal-title":"Drug Saf"},{"issue":"5","key":"2021120823450165600_B14","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1111\/j.1529-8019.2009.01260.x","article-title":"Clinical risk management of Stevens-Johnson syndrome\/toxic epidermal necrolysis spectrum","volume":"22","author":"Knowles","year":"2009","journal-title":"Dermatol Ther"},{"issue":"10","key":"2021120823450165600_B15","first-page":"2494","article-title":"Intravenous immunoglobulin therapy for children with Stevens-Johnson syndrome","volume":"27","author":"Morici","year":"2000","journal-title":"J Rheumatol"},{"issue":"6 pt 1","key":"2021120823450165600_B16","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1542\/peds.112.6.1430","article-title":"Use of intravenous immunoglobulin in children with stevens-johnson syndrome and toxic epidermal necrolysis: seven cases and review of the literature","volume":"112","author":"Metry","year":"2003","journal-title":"Pediatrics"},{"issue":"4","key":"2021120823450165600_B17","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1097\/MOP.0b013e32832d1fef","article-title":"An update on Stevens-Johnson syndrome and toxic epidermal necrolysis in children","volume":"21","author":"Koh","year":"2009","journal-title":"Curr Opin Pediatr"},{"issue":"2","key":"2021120823450165600_B18","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/S1607-551X(09)70045-2","article-title":"Oxcarbazepine-induced Stevens-Johnson syndrome: a case report","volume":"25","author":"Lin","year":"2009","journal-title":"Kaohsiung J Med Sci"},{"issue":"4","key":"2021120823450165600_B19","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.bjps.2004.12.007","article-title":"Intravenous immunoglobulins and plasmapheresis combined treatment in patients with severe toxic epidermal necrolysis: preliminary report","volume":"58","author":"Lissia","year":"2005","journal-title":"Br J Plast Surg"},{"issue":"4","key":"2021120823450165600_B20","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1111\/j.1365-2133.2010.09863.x","article-title":"Open trial of ciclosporin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"163","author":"Valeyrie-Allanore","year":"2010","journal-title":"Br J Dermatol"},{"issue":"1","key":"2021120823450165600_B21","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1001\/archderm.1993.01680220104023","article-title":"Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme","volume":"129","author":"Bastuji-Garin","year":"1993","journal-title":"Arch Dermatol"},{"issue":"4","key":"2021120823450165600_B22","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1067\/mjd.2002.127249","article-title":"Treatment of toxic epidermal necrolysis with intravenous immunoglobulin in children","volume":"47","author":"Tristani-Firouzi","year":"2002","journal-title":"J Am Acad Dermatol"},{"issue":"5 pt 1","key":"2021120823450165600_B23","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S0190-9622(96)90732-X","article-title":"Mycoplasma pneumoniae infection is associated with Stevens-Johnson syndrome, not erythema multiforme (von Hebra)","volume":"35","author":"Tay","year":"1996","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"2021120823450165600_B24","doi-asserted-by":"crossref","first-page":"398","DOI":"10.4103\/0378-6323.18943","article-title":"Efficacy of low dose intravenous immunoglobulins in children with toxic epidermal necrolysis: an open uncontrolled study","volume":"71","author":"Mangla","year":"2005","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"2021120823450165600_B25","first-page":"205","article-title":"Treatment of toxic epidermal necrolysis (TEN) with low dose intravenous immunoglobulin in child","volume":"20","author":"Habib","year":"2010","journal-title":"J Coll Physicians Surg Pak"},{"issue":"4","key":"2021120823450165600_B26","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1027\/0838-1925.14.4.143","article-title":"Cutaneous adverse drug reactions: Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"14","author":"Mockenhaupt","year":"2002","journal-title":"Allergy Clin Immunol Int"},{"issue":"10","key":"2021120823450165600_B27","first-page":"2234","article-title":"The risk of Stevens-Johnson syndrome and toxic epidermal necrolysis associated with nonsteroidal antiinflammatory drugs: a multinational perspective","volume":"30","author":"Mockenhaupt","year":"2003","journal-title":"J Rheumatol"},{"issue":"19","key":"2021120823450165600_B28","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1056\/NEJM199411103311906","article-title":"Severe adverse cutaneous reactions to drugs","volume":"331","author":"Roujeau","year":"1994","journal-title":"New Engl J Med"},{"issue":"6","key":"2021120823450165600_B29","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1172\/JCI113798","article-title":"Anticonvulsant hypersensitivity syndrome: in vitro assessment of risk","volume":"82","author":"Shear","year":"1988","journal-title":"J Clin Invest"},{"issue":"4","key":"2021120823450165600_B30","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1097\/ACI.0b013e3282370c5f","article-title":"Human leukocyte antigens and drug hypersensitivity","volume":"7","author":"Chung","year":"2007","journal-title":"Curr Opin Allergy Clin Immunol"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/128\/4\/723\/1056492\/zpe01011000723.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/128\/4\/723\/1056492\/zpe01011000723.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,9]],"date-time":"2021-12-09T04:56:11Z","timestamp":1639025771000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/128\/4\/723\/30701\/Recurrence-and-Outcomes-of-Stevens-Johnson"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10,1]]},"references-count":30,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2011,10,1]]},"published-print":{"date-parts":[[2011,10,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2010-3322","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,10,1]]}}}